ravulizumab

Conditions Treated

Ravulizumab is used to manage specific rare diseases by preventing the immune system from damaging healthy tissues. It is approved for the following uses:

• Paroxysmal Nocturnal Hemoglobinuria (PNH): A condition where red blood cells are broken down too quickly by the immune system, which can lead to anemia and blood clots.
• Atypical Hemolytic Uremic Syndrome (aHUS): A disease that causes abnormal blood clots to form in small blood vessels, potentially leading to kidney failure. It is used in both adults and children.
• Generalized Myasthenia Gravis (gMG): Used in adults who are anti-acetylcholine receptor (AChR) antibody-positive. This condition causes severe muscle weakness that can affect movement and breathing.
• Neuromyelitis Optica Spectrum Disorder (NMOSD): Used in adults who are anti-aquaporin-4 (AQP4) antibody-positive. This is an inflammatory disease that affects the optic nerves and spinal cord.

This medication is typically used as a long-term treatment to help reduce symptoms, prevent disease relapses, and lower the risk of life-threatening complications associated with these conditions.

The Complement System

Ravulizumab belongs to a class of medicines known as complement inhibitors. The complement system is a group of proteins in the blood that are part of the body's natural immune response. While this system usually helps fight off bacteria and viruses, in certain medical conditions, it can become overactive and begin attacking the body's own healthy cells.

Targeting the C5 Protein

This medication works by specifically binding to a protein called C5. By attaching to this protein, ravulizumab prevents it from breaking down into other substances that trigger inflammation and cell destruction. This process is often referred to as blocking the complement cascade.

How It Helps Specific Conditions

By inhibiting the complement system, ravulizumab helps manage several different disorders:

• Paroxysmal Nocturnal Hemoglobinuria (PNH): It prevents the immune system from breaking down red blood cells too quickly.
• Atypical Hemolytic Uremic Syndrome (aHUS): It stops the immune system from creating tiny blood clots that can damage the kidneys and other organs.
• Generalized Myasthenia Gravis (gMG) and NMOSD: It reduces the immune-mediated attack on the nervous system and muscles, which helps improve strength and reduce symptoms.

Ravulizumab is designed to stay in the body for a long time, which allows for a longer period between treatments compared to some other similar medications.

Common Side Effects

Commonly reported side effects of ravulizumab include:

• Headache
• Diarrhea
• Nausea or vomiting
• Upper respiratory tract infections, such as the common cold
• Pain in the joints, back, or muscles
• Dizziness
• Fatigue
• Fever

Serious Side Effects

Some side effects can be serious. Contact a healthcare provider immediately if you experience:

• Signs of infection: Fever, chills, muscle aches, severe headache with nausea or vomiting, stiff neck, or sensitivity to light.
• Severe allergic reactions: Hives, rash, swelling of the face or throat, and difficulty breathing.
• Infusion-related reactions: Chest pain, shortness of breath, or feeling faint during or after the treatment.
• Changes in blood pressure: Significant increases in blood pressure levels.

Serious Meningococcal Infections

Ravulizumab increases the risk of life-threatening meningococcal infections. Because of this risk, the medication is only available through a restricted distribution program. Healthcare providers must provide a Patient Safety Card that should be carried at all times during treatment and for eight months after the final dose.

Vaccination Requirements

Individuals must receive meningococcal vaccines at least two weeks before starting ravulizumab. If treatment is urgent and cannot wait, antibiotics are typically prescribed to be taken until the vaccine becomes effective. Vaccination does not eliminate the risk of infection, but it reduces it. It is also necessary to stay up to date with booster shots as recommended by a healthcare provider.

Recognizing Symptoms

Immediate medical care is necessary if symptoms of a meningococcal infection appear, including:

• Fever with a headache and stiff neck
• Nausea or vomiting
• Confusion
• Sensitivity to light
• Muscle aches and flu-like symptoms
• A rash that does not fade when pressed

Other Infection Risks

Because ravulizumab suppresses part of the immune system, there is an increased risk of other serious infections, such as those caused by Streptococcus pneumoniae and Haemophilus influenzae. Patients should be up to date on vaccinations for these bacteria before starting therapy.

Infusion-Related Reactions

Infusion reactions can occur during or after the administration of this drug. Monitoring by a healthcare professional is required during the infusion and for at least one hour afterward to check for signs of an allergic reaction, such as difficulty breathing, chest pain, or swelling.

Contraindications

Ravulizumab should not be started in individuals who currently have a meningococcal infection.

Pregnancy

There is limited information regarding the safety of ravulizumab use during pregnancy. Because ravulizumab is a monoclonal antibody, it is expected to cross the placental barrier and reach the developing fetus. Animal studies have indicated potential risks to fetal development, but adequate and well-controlled studies in humans are currently unavailable.

If you are pregnant or planning to become pregnant, it is important to discuss the potential benefits of treatment against the possible risks to the fetus with your doctor. Healthcare providers typically evaluate whether the clinical need for the medication outweighs the potential risks.

Breastfeeding

It is currently unknown whether ravulizumab passes into human breast milk. There is also no data available regarding the medication's effects on a breastfed infant or its impact on milk production. Because many drugs are excreted in human milk and the potential for serious adverse reactions in nursing infants is unknown, you should consult your healthcare provider before breastfeeding while using this medication.

Available Forms

Ravulizumab is provided in the following forms:

• Intravenous Infusion: A concentrated solution that is diluted and administered into a vein by a healthcare professional.
• Subcutaneous Injection: A solution administered under the skin using a specialized on-body delivery system.

FDA Approval and Indications

Ravulizumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of the following conditions in adults and, in some cases, children:

• Paroxysmal nocturnal hemoglobinuria (PNH).
• Atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
• Generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.
• Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive.

Boxed Warning and Safety Programs

The FDA has issued a boxed warning for ravulizumab because it increases the risk of serious and life-threatening meningococcal infections. These infections can become rapidly fatal if not recognized and treated early.

Due to this risk, the drug is only available through a restricted program called a Risk Evaluation and Mitigation Strategy (REMS). Healthcare providers must be certified in the program, and patients must be informed of the risks. Patients are generally required to receive a meningococcal vaccine at least two weeks before starting treatment, unless the need for urgent treatment outweighs the risk of delaying therapy.

Regulatory History

Ravulizumab was first approved by the FDA in 2018. It is classified as a long-acting complement inhibitor, designed to require less frequent dosing than earlier medications in its class.

Factors Influencing Cost

The total cost of treatment with ravulizumab depends on several variables, including the specific medical condition being treated and the patient's body weight, which determines the required dosage. Because it is a biologic medication administered by healthcare professionals, costs also include the fees associated with the infusion or injection process at a hospital or clinic.

Insurance and Assistance

Insurance coverage varies by provider and plan. Many patients may have high out-of-pocket expenses, such as deductibles or coinsurance. Financial assistance programs or copay support may be available through the drug manufacturer for those who qualify based on financial need or insurance status.

Generic Options

Currently, there are no generic or biosimilar versions of ravulizumab available. Biologic drugs are complex to manufacture and are usually protected by patents for several years, which contributes to their higher cost compared to standard chemical drugs.